Skip to content

Feasibility study of adjuvant laparoscopic hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer at high risk of peritoneal carcinomatosis

Feasibility study of adjuvant laparoscopic hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer at high risk of peritoneal carcinomatosis - Lap. HIPEC study

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON36646
Enrollment
10
Registered
2011-03-21
Start date
2011-01-01
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

peritoneal cancer

Interventions

The laparoscopic HIPEC procedure: open introduction of a 10 mm trocar at the umbilicus, CO2 pneumoperitoneum, three additional trocars of 10 mm, complete dissection of adhesions, peritonectomy or ot

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed with adenocarcinoma of the colon and proximal rectum and at least one of the following risk factors for PC will be considered for inclusion: * pT4 * (Resected) local peritoneal nodules in the close proximity of the primary tumour * Primary tumour presenting with obstruction and/or perforation * Positivie cytology in peritoneal lavage * Ovarian metastasis or omental metastasis;Eligibility criteria are: * age between 18 and 75 years, * ECOG performance status 0 to 2, * written informed consent obtained prior to any study specific screening procedures, * white blood cell count at least 3000/mm3, platelet count at least 100.000/mm3, * no bleeding diathesis or coagulopathy, * creatinine normal or creatinine clearance at least 50 ml/min

Exclusion criteria

Exclusion criteria: * liver and/or lung metastases, * pregnant or lactating women, * unstable or uncompensated respiratory or cardiac disease, * serious active infections, * other concurrent chemotherapy.

Design outcomes

Primary

MeasureTime frame
Primary endpoint is hospital stay.

Secondary

MeasureTime frame
Secondary endpoints are treatment related morbidity defined as surgical complications and toxicity related to the intraperitoneal chemotherapy.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)